1-phosphono-4-(3-phenoxyphenyl) butylsulfonic acid tripotassiuM salt
| 中文名称 | 1-phosphono-4-(3-phenoxyphenyl) butylsulfonic acid tripotassiuM salt |
|---|---|
| 中文同义词 | 化合物 T10587;化合物 BPH-652 |
| 英文名称 | 1-phosphono-4-(3-phenoxyphenyl) butylsulfonic acid tripotassiuM salt |
| 英文同义词 | 1-phosphono-4-(3-phenoxyphenyl) butylsulfonic acid tripotassiuM salt;BPH-652;FIOQVVKPUBNHEM-UHFFFAOYSA-N;BPH 652,BPH652 |
| CAS号 | 157124-84-0 |
| 分子式 | C16H16K3O7PS |
| 分子量 | 500.627701 |
| EINECS号 | |
| 相关类别 | |
| Mol文件 | 157124-84-0.mol |
| 结构式 | ![]() |
1-phosphono-4-(3-phenoxyphenyl) butylsulfonic acid tripotassiuM salt 性质
| 储存条件 | 4°C, away from moisture |
|---|---|
| 形态 | 固体 |
| 颜色 | 白色至米白色 |
| 水溶解性 | Water : 25 mg/mL (49.94 mM; Need ultrasonic) |
Ki: 1.5 nM (CrtM).
IC50: 100-300 nM (
S. aureus
pigment formation).
BPH-652 treatment (0.5 mg twice per day (days −1, 0, 1, and 2), Intraperitoneal injection) significantly lowers S. aureus bacterial counts in the kidneys of the mice than those of the control group (P < 0.001), with 8 of 13 below the detection threshold, versus only 2 of 14 in the control group; on average, this result corresponds to a 98% decrease in surviving bacteria in the treatment group.
| Animal Model: | A systemic S. aureus infection model in mice. |
| Dosage: | 0.5 mg twice per day (days −1, 0, 1, and 2). |
| Administration: | Intraperitoneal injection. |
| Result: | S. aureus bacterial counts in the kidneys of the mice treated with BPH-652 were significantly lower than those of the control group. |
安全信息
| 更新日期 | 产品编号 | 产品名称 | CAS号 | 包装 | 价格 |
|---|---|---|---|---|---|
| 2026/09/15 | HY-16115 | BPH-652 | 157124-84-0 | 1 mg | 2100元 |
| 2026/09/15 | HY-16115 | 1-phosphono-4-(3-phenoxyphenyl) butylsulfonic acid tripotassiuM salt BPH-652 | 157124-84-0 | 5mg | 5185元 |
